Towards this goal, several studies have been conducted demonstrating the effectiveness of some JNK inhibitors in the protection against pathophysiology features of experimentally induced IBD in some in vivo models [46], [47]. This evidence concerns the gene MAPK8 and inflammatory bowel disease.